spreading the news....June 07, 2007]
www.streetinvesting.com: Continuing review on Mistral Pharma Inc.
(M2 PressWIRE Via Thomson Dialog NewsEdge)
RDATE:07062007
Please visit www.Streetinvesting.com for the full report.
Wall Street descended into further fuddles this Wednesday due to
speculation of a probable rate hike announcement from the Federal
Reserve. The European Central Bank, on the other hand, pushed forward a
raise in rate which triggered a backlash on the European stock fueling
the already battered investors' trepidation in US markets. Labor costs
startling climb and home depot taking a rain check in the US are adding
to the building inflationary pressure. Mistral Pharma Inc. (TSX
Venture: MIP) which has been keeping a constant pattern throughout its
four last trading sessions, finished $0.05 even at the Bell on Tuesday
5th of June with a trading volume of 219,000.
Our main focus recently has been the Canadian Exchange, and our capable
research team has been looking into the pool of promising companies of
which we will bring you insight. Mistral Pharma Inc. was an eye catcher
for many and we are once again bringing it to your attention.
Hitting the news room on Wednesday,06th Jun, 2007 Mistral Pharma Inc.
announced that it has filed a provisional patent application with the
United States Patent and Trademark Office (USPTO) for a new oral drug
delivery platform to be used in some of its pipeline development
projects. This oral drug delivery platform was developed by Mistral's
Vice President of R&D, Dr. Alain Desjardins and senior formulator
Najiba Dernaoui. The patent application was filed by the Montreal
office of Bereskin & Parr, a leading patent agent firm.
"The filing of this patent application shows that Mistral can count on
an additional oral delivery platform, which increases the versatility
of our technology portfolio" said Mr. Bertrand F. Bolduc, Mistral's
president & CEO. "In addition to ProciseTM, SavitTM and ChronopTM,
Mistral can use at least two other platforms in order to develop
optimal oral drug delivery formulations" he added.
Mistral Pharma is an innovative pharmaceutical product development and
drug delivery company and its first two branded products, MIST-B01 &
B02, showed positive results at their respective first pilot clinical
trials. Mistral also have the Canadian rights to Instillagel , a local
anesthetic and antiseptic combination product used for urology
procedures which is expected to be launched in Canada during Q4 2007.
Mistral positions itself as a development and marketing partner for
pharmaceutical companies.
With the market flirting with terms like inflation, rate hike, labor
costs rise and others sending a tremor of doubt, Streetinvesting.com is
increasing curious to see what the future reserves for this company.
Our research team will be regularly offering updates on this company's
development as they post them to the general public.